Figure 3

Optimization of anti-CTLA-4 dosing in combination with GVAX immunotherapy. A: Titration of anti-CTLA-4 using once per week dosing. Top panel: experimental design. Bottom panel: CTL function in ProHA x TRAMP mice. 5 animals per group, representative of 2 experiments. B: Titration of anti-CTLA-4 using twice per week dosing. Top panel: experimental design. Bottom panel: CTL function in ProHA x TRAMP mice. 5 animals per group, representative of 2 experiments. C: Comparison of single versus divided dosing of anti-CTLA-4 per week. Top panel: experimental design. Bottom panel: CTL function in ProHA x TRAMP mice. 5 animals per group, representative of 2 experiments.*P < 0.05. D: Prostate directed expansion of specific CD8 cells: Top panel: experimental schema. Bottom panels: Absolute numbers of CD8 T cells harvested from prostate or prostate draining lymph nodes. Left: Absolute number of IFN-γ positive (by intracellular staining) CD8 T cells in those locations. 3 animals per group, representative of 2 experiments. *P < 0.01 (GVAX/α-CTLA-4 mAb vs. GVAX alone).